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Hospital, Eindhoven, The Netherlands.BACKGROUND For clinicians, conﬁdence in atrial ﬁbrillation (AF)
episode classiﬁcation is an important consideration when electing
to use insertable cardiac monitors (ICMs).
OBJECTIVE The purpose of this study was to report on the
improved AF detection algorithm in the Reveal LINQ ICM.
METHODS The Reveal LINQ Usability Study is a nonrandomized,
prospective, multicenter trial. The ICM has been miniaturized, uses
wireless telemetry for remote patient monitoring, and its AF
algorithm includes a new p-wave ﬁlter. At 1 month post-device
insertion, Holter monitor data were collected and annotated for
true AF episodes ≥2 minutes, and performance metrics were
evaluated by comparing Holter annotations with ICM detections.
RESULTS The study enrolled 151 patients (age 56.6 ± 12.1, male
67%). Reasons for monitoring included AF ablation or AF management
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10.1016/j.hrthm.2016.03.005indications in 5.9% (n¼ 9) of patients. Of the 138 patients with an
analyzable Holter recording, a total of 112 true AF episodes were
identiﬁed in 38 patients (27.5%). The overall accuracy of the ICM to
detect durations of AF or non-AF episodes was 99.4%, and the AF
burden measured by the ICM was highly correlated with the Holter
(Pearson coefﬁcient 0.995).
CONCLUSION The new AF detection algorithm in the Reveal LINQ
ICM accurately detects the presence or absence of AF. Additionally,
it showed high sensitivity in detecting AF duration in patients with
a history of intermittent and symptomatic AF.
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Atrial ﬁbrillation (AF) is a common cardiac arrhythmia that
affects millions of people worldwide, with an estimated 2.2
million people in the United States and 4.5 million in the
European Union.1 The causes of AF are numerous, varied,
and multifactorial, and the symptoms range from nonexistent
to severe (e.g., fatigue, palpitations, dyspnea, hypotension,
syncope, heart failure).2 AF is associated with an increased
incidence of frequent hospitalizations, hemodynamic abnor-
malities, thromboembolic events (stroke and transient ische-
mia attack), and heart failure resulting in signiﬁcant
morbidity and mortality.3,4 AF can be distinguished and
classiﬁed as paroxysmal, persistent, long-standing persistent,
or permanent based on the frequency and duration ofrt Rhythm Society. http://dx.doi.org/Open access under CC BY-NC-ND license.
Heart Rhythm, Vol 13, No 7, July 20161426episodes. It has been suggested that the adverse effects of AF
have been correlated to episode duration and to the amount
of time during which the heart is in AF, the so-called AF
burden.5–7 Therefore, such a characterization is clinically
relevant with regard to the selection and outcome of the
therapeutic approach.
Diagnosis of AF is usually based on the patient’s clinical
history and physical examination, and is conﬁrmed by ECG.
Patients suffering from symptoms have an increased like-
lihood that AF is diagnosed. However, studies have shown
poor correlation between symptoms and occurrence of
AF.8,9 Because medical management of AF patients is
currently primarily based on symptoms, there is concern
that asymptomatic, undetected events of AF could expose
patients to increased risk of ischemic stroke and throm-
boembolic events.10 External cardiac monitors, such as
Holter monitors and mobile cardiac telemetry, are among
the most frequently used tests in cardiology. However, the
yield of short-term monitoring is limited, and patient
compliance with prolonged external monitoring is inversely
proportional to the prescribed duration. Instead, continuous
monitoring of AF is clearly superior and more efﬁcient than
any other method.5,11
Insertable cardiac monitors (ICMs) with dedicated AF
algorithms have been introduced into clinical practice for
the diagnosis and monitoring of AF in various clinical
applications, such as recurrent AF diagnosis after surgi-
cal12 or catheter AF ablation,9,13,14 and cryptogenic
stroke.15,16 ICMs have been shown to have high accuracy
in detecting AF burden using incoherence of R-R intervals
over a period of time,17,18 and high diagnostic accuracy
due to the ability of long-term continuous 24/7 monitoring,
particularly in patients with paroxysmal or asymptomatic
AF.12,19 Besides the improved AF algorithm,18,20 the
Reveal LINQ ICM is only 7 × 45 × 4 mm in size, making
it 87% smaller than its predecessor. It has improved
electrode coating and is inserted using a standardized
technique that forms a tight pocket to improve the quality
of the ECG signal. Our hypothesis is that the new p-wave
enhanced AF algorithm should contribute to improve the
quality of the signal and the performance of the device.
Therefore, the main objective of this study was to assess
the AF diagnostic, duration detection, and episode detec-
tion accuracy of the ICM.Methods
Study design
The Reveal LINQ usability study is a prospective multicenter
single-arm clinical study (ClinicalTrials.gov Identiﬁer:
NCT01965899). All patients provided written informed
consent, and the study protocol was reviewed and approved
by the Human Research Ethics Committee of each partic-
ipating institution. The study was prospectively designed to
have 2 phases, the ﬁrst enrolling 30 patients with any
indication for an ICM and the second enrolling 121 patients
with a documented history of AF and ablation candidates.Data collection
Patients were followed for 1 month after insertion of a
Reveal LINQ ICM (Medtronic plc, Dublin, Ireland). Data
were collected at baseline, insertion, and 1-month follow-up
visit. At the 1-month follow-up visit, Holter monitoring was
performed for 24 hours, during which the ICM continuously
uploaded ECG and detected episode information to the
Holter. The Holter monitor also stored 2 leads of surface
ECG information, which was used to annotate the Holters
along with the ECG recorded by the ICM. After the 1-month
follow-up visit, patients were instructed to complete a
manual transmission of the data stored in their devices at
least once a month.
Device and AF algorithm
The AF detection algorithm is based on both an R-R interval
and a P-wave evidence score. The P-wave evidence score
reduces inappropriate AF detections in the original R-R
interval pattern–based algorithm and leverages the evidence
of a single P wave between two R waves using morphologic
processing of the ECG signal. The algorithm makes a rhythm
classiﬁcation every 2 minutes. When an episode is detected
at the end of a 2-minute detection period, the ﬁrst 2 minutes
of the ECG from that episode are stored in the device. The
device can store up to 14 AF episodes with ECG; afterward,
the earliest episode is overwritten by newer episodes. The
longest AF episode detected (≥10 minutes) is always
preserved in memory until a full manual transmission is
done. Every night, the ICM wirelessly transmits the last 10
seconds of the 2-minute ECG segment for the longest
episode of the day. In addition to the nightly wireless
transmissions, the patient can manually transmit the full
information on all episodes stored in memory at any given
time.
Holter and episode annotation
Two reviewers interpreted both channels of the surface ECG
and the Reveal LINQ ECG to annotate for the presence of
atrial tachycardia (AT) or AF during the 24-hour recordings.
All episodes410 seconds in duration were annotated during
the review process. Segments in which the Holter was not
interpretable on all 3 ECGs because of noise or motion
artifact were marked as uninterpretable segments. The
reviewers were blinded to the device episode detection
information during the annotation process. No episodes
recorded by the Holter were overwritten.
Statistical analysis
The baseline characteristics of all patients enrolled in the
study are reported along with the indication for the ICM. The
Holter annotations for true AF episodes were compared with
the AF detections from the ICM device (Figure 1). Only true
AF episodes that were annotated as ≥2 minutes in duration
were used for data analysis. AT or atrial ﬂutter episodes,
uninterpretable segments, or periods with missing telemetry
signals from the ICM were excluded from the data analysis.
Figure 1 Deﬁnitions used for performance metrics. Deﬁnitions of true positive (TP), false positive (FP, false negative (FN), and true negative (TN) episode
and duration used for computation of episode and duration detection performance metrics. AF ¼ atrial ﬁbrillation; ICM ¼ insertable cardiac monitor.
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metrics (sensitivity, speciﬁcity, positive predictive value
[PPV], negative predictive value [NPV], and accuracy) were
evaluated by comparing Holter annotations with ICM
detections. Duration-based metrics were calculated based
on the overlap of the duration of time between periods
annotated as AF and periods detected as AF by the ICM
(Figure 1). Patient-based metrics, also called diagnostic
metrics,20 evaluate the ability of the ICM to detect the
presence or absence of AF within a patient and were
calculated as shown in Figure 2.
Episode-based metrics evaluated the proportion of true
episodes and detected episodes that were appropriately
identiﬁed. Generalized estimating equation estimates, which
adjust for multiple episodes in a patient, and the possible
correlation of AF detection performance on episodes from
the same Holter recording, were also computed for episodeFigure 2 Deﬁnitions used for patient-based metrics. Deﬁnitions of true positive
were determined by diagnosis based on Holter results compared to insertable carddetection sensitivity and PPV. Episode detection NPV and
speciﬁcity could not be computed because a true negative
episode cannot be deﬁned. The AF burden determined by the
ICM was compared with the reference AF burden by
calculating the Pearson correlation coefﬁcient between the
paired measurements. The study required all inserted devices
to be programmed at nominal settings. Results are reported
for all patients “as programmed” during the Holter period.Results
The study enrolled a total of 151 patients, of whom 1 patient
was exited before 1 month without any Holter monitoring.
The baseline characteristics of the enrolled patients are listed
in Table 1. Mean age of patients was 56.6 ± 12.1 years, and
66.9% were male. There was a history of stroke or transient
ischemic attack in 8.6%, paroxysmal AF in 66.9%, persistent(TP), false positive (FP), false negative (FN), and true negative )TN) patients
iac monitor (ICM). AF ¼ atrial ﬁbrillation.
Table 1 Baseline demographics of patients enrolled in the study
Patient characteristics
Enrolled subjects
(N ¼ 151)
Gender
Male 101 (66.9%)
Female 50 (33.1%)
Age (mean ± SD) 56.6 ± 12.1
Primary indication for implant
Syncope 19 (12.6%)
Palpitations/suspected AF 7 (4.6%)
Cryptogenic stroke 1 (0.7%)
AF ablation monitoring/AF management 123 (81.5%)
Other 1 (0.7%)
Supraventricular tachycardia 130 (86.1%)
Atrial ﬁbrillation 126 (83.4%)
Paroxysmal 101 (66.9%)
Persistent 27 (17.9%)
Permanent 2 (1.3%)
Atrial ﬂutter/atrial tachycardia 24 (15.9%)
Stroke/transient ischemic attack 13 (8.6%)
Bradycardia–tachycardia syndrome 1 (0.7%)
Sinus node dysfunction 17 (11.3%)
Values are given as no. (%) unless otherwise indicated.
AF ¼ atrial ﬁbrillation.
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syndrome in 0.7%. The indication for an ICM was syncope
in 19 patients (12.6%), cryptogenic stroke in 1 (0.7%),
palpitations or suspected AF in 7 (4.6%), and AF ablation or
AF management in 123 (81.5%). A Holter was performed in
150 patients, of which 141 were suitable for analysis after
excluding recordings with technical issues, such as loss of
telemetry or inability to process the data. After exclusion of
recorded segments with missing telemetry or uninterpretable
surface ECG and periods of AT, a total of 3188 hours of
valid recording time from 138 patients were analyzed,
yielding a mean valid recording time of 23.1 hours per
patient. True AF was observed in 38 of the 138 patients
included in the data analysis, yielding a total of 112 true AF
episodes ≥2 minutes and 450 hours of AF.
The ICM correctly identiﬁed 37 of the 38 patients with
Holter-detected AF (diagnostic sensitivity of 97.4%) and 97
of the 100 patients without AF according to Holter analysis
(diagnostic speciﬁcity of 97.0%). On the other hand, the ICM
algorithm identiﬁed a total of 40 patients with AF, of whom
37 had Holter-detected AF (diagnostic PPV of 92.5%), and
98 patients without AF, of whom 97 also showed absence of
AF by Holter (diagnostic NPV of 99.0%).
Table 2 lists ICM performance results, expressed as gross
and patient averages. For every 100 hours of true AF, the
algorithm correctly detected 98.4 hours as AF (gross
duration sensitivity of 98.4%), and for 100 hours of normal
sinus or other non-AF rhythms the algorithm inappropriately
detected 0.5 hours as AF (gross duration speciﬁcity of
99.5%). The overall duration or AF burden accuracy, deﬁned
as the proportion of total correctly identiﬁed duration, was
99.4%. The AF burden detected by both ICM and Holter
showed a high Pearson correlation coefﬁcient of 0.995
(Figure 3). The ICM detected 109 of 112 episodes of trueAF ≥2 minutes in duration (gross episode sensitivity of
97.3%), and of all 365 episodes detected by the algorithm
across patients, 273 of them were true AF (gross episode
PPV of 74.8%). Furthermore, for 100 patients with ICM
detected episodes, 90 had at least 1 episode with true AF
(patient averaged episode PPV of 90.4%).
During the Holter monitoring period, 5 patients (3.6%)
had ≥1 inappropriate ICM-detected episode. Two patients
(1.4%) accounted for nearly 92.4% of inappropriately
detected episodes, whereas 2 patients had both appropriate
and inappropriate detections. A total of 92 inappropriately
detected episodes contributed to only 12.2 hours of detected
duration, with a median episode duration of 4 minutes. For
all detected episodes (≥2 minutes), the “gross” episode PPV
was 74.8% and progressively improved to 83.8%, 97.1%,
and 100% for detected episodes ≥6 minutes, 1 hour, and 6
hours respectively. The gross episode sensitivity improved
from 97.3% for true episodes ≥2 minutes to 98.7%, 100.0%,
and 100% for episodes 6 ≥minutes, 1 hour, and 6 hours
respectively.
During the monitoring period, the Holters detected 134
AF episodes in 11 patients that were ≥30 seconds and o2
minutes. Of these 134 episodes, 17 overlapped with an
episode indicated by the device and therefore were detected
by the ICM. One patient had only 1 episode between 30
seconds and o2 minutes but no other episodes. Another
patient had 2 episodes between 30 seconds and 2 minutes,
but no episodes 42 minutes.Discussion
For patients with diagnosed AF, guidelines exist to initiate
therapy both with heart rate control and/or antiarrhythmic
therapy, whereas in patients with stroke risk factors, anti-
coagulation treatment is recomended.21 However, several
factors can hinder AF diagnosis, including “silent AF,” poor
correlation between patient symptoms and AF episodes,
intermittency, and brevity of episodes (e.g., paroxysmal AF),
as well as the short duration of standard ECG monitoring.
Several studies have effectively demonstrated a substantial
incidence of previously undiagnosed AF in patients with
cryptogenic stroke, and the presence and time course of
recurrent AF after ablation by using an ICM.9,13–16,22 A
relationship between relatively short episodes of AF and an
increased risk for thromboembolism has been shown as
well.7,23 In fact, one of the main challenges clinicians have is
accurately identifying patients with AF and quantifying AF
burden in order to implement the most appropriate thera-
peutic regimen and prevent complications such as stroke.
The goal of ICMs is to overcome these challenges.
In this study, we measured the performance of the new p-
wave enhanced AF detection algorithm of Reveal LINQ in a
multicenter clinical trial for remote monitoring of patients
with known or suspected arrhythmias. We report positive
results with regard to (1) high sensitivity in detecting the
presence of AF; (2) high speciﬁcity and PPV; (3) high
reliability in conﬁrming freedom from AF, as shown by the
Table 2 Duration and episode detection performance during the Holter monitoring period
Performance metrics Reveal LINQ* Reveal XT†
Patients with analyzable Holter 138 206
Duration-based results
Sensitivity (%)
Gross 98.4 98.1
Patient average 93.7 89.0
Speciﬁcity (%)
Gross 99.5 98.5
Patient average 99.6 91.3
Positive predictive value (%)
Gross 97.2 91.9
Patient average 90.6 75.2
Negative predictive value (%)
Gross 99.7 99.7
Patient average 96.4 97.1
Accuracy (%)
Gross 99.4 98.5
Patient average 99.4 98.5
Episode-based results
Episode sensitivity (%)
Gross 97.3 85.2
Patient average 97.2 87.9
GEE estimate (95% CI) 97.1 (97.1–97.2) 88.2 (82.0–92.5)
Episode positive predictive value (%)
Gross 74.8 38.8
Patient average 90.4 73.6
GEE estimate (95% CI) 90.4 (77.6–96.2) 73.5 (64.5–81.0)
Patient-based results (%)
Sensitivity 97.4 96.1
Speciﬁcity 97.0 85.4
Positive predictive value 92.5 79.3
Negative predictive value 99.0 97.4
Accuracy 97.1 89.3
CI ¼ conﬁdence interval; GEE ¼ generalized estimating equation.
*Detection performance data from LINQ Usability Study.
†Detection performance data from XPECT Study.17
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Reveal LINQ correctly detected 98.4% of the total AF
duration and 99.5% of the total normal sinus rhythm
(Table 2). In addition, at the episode level, 74.8% of
the detected AF episodes were correctly classiﬁedFigure 3 Comparison of atrial ﬁbrillation (AF) burden by insertable
cardiac monitor (ICM) and Holter. AF burden measured by the ICM
compared with AF burden calculated from the annotated Holter recording
for all patients. r ¼ Pearson correlation coefﬁcient.(Table 2). The performance numbers are signiﬁcantly better
compared to the previous generation device (Reveal
XT),17,20 showing a clear improvement in terms of AF
detection capabilities, particularly in reducing the number of
false-positive events (Table 2).
The ability of the device to keep in storage the longest AF
episode detected (≥10 minutes) between 2 full manual
transmissions and also wirelessly transmit the longest
episode of the day at midnight is an important feature, based
on the higher accuracy of the device for longer episodes.
Thus, there is a higher likelihood that a true AF episode will
be stored for review without being overwritten. Based on
these data, from a practical standpoint, physicians can
conﬁdently diagnose AF via either the full manual inter-
rogation or the automatic transmission. The decision to take
clinical actions for shorter or longer burden is at the
physician’s discretion. Our results showed an AF burden
accuracy of 99.4% and an improvement of PPV with longer
episode duration.
In addition to our results, the reduced size, improved
electrode coating, and simpliﬁed insertion procedure that
forms a tight pocket and improves the quality of the ECG
signal position this new ICM as a reliable tool for diagnosis
Heart Rhythm, Vol 13, No 7, July 20161430of patients with asymptomatic AF and for long-term manage-
ment of patients with a known history of intermittent and
symptomatic AF.
Study limitations
One of the main limitations of this study is that the
comparison between the Holter annotations and the device-
detected episodes is limited to 24 hours. In addition, only AF
episodes ≥2 minutes in duration were included in the
analysis; therefore, the study results are not applicable to
episodes that are shorter than 2 minutes. The study also
focused on AF detection and did not address ICM perform-
ance with regard to AT and atrial ﬂutter detection. Finally,
most patients in the relatively small study cohort have a
known history of AF, leading to a high disease prevalence.
PPV and NPV values will differ in patient populations with a
different disease prevalence. However, sensitivity and spe-
ciﬁcity will remain unaffected by disease prevalence.
Conclusion
The new AF detection algorithm in the Reveal LINQ ICM
showed an improvement in terms of AF detection capabil-
ities compared to its predecessor, showing high sensitivity,
speciﬁcity, and PPV values. Reveal LINQ represents a
valuable diagnostic tool in patients with suspected AF.
Acknowledgments
We thank all the Reveal LINQ Usability investigators for
their hard work and participation in the study. We also thank
Mirko de Melis, Tracy Bergemann, and Noreli Franco for
help with data and statistical analysis and manuscript review.
References
1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks
G, Kirchhof P, Guidelines-CPG ESCCfP, Document R. 2012 focused update of
the ESC Guidelines for the management of atrial ﬁbrillation: an update of the
2010 ESC Guidelines for the management of atrial ﬁbrillation—developed with
the special contribution of the European Heart Rhythm Association. Europace
2012;14:1385–1413.
2. Wattigney WA, Mensah GA, Croft JB. Increased atrial ﬁbrillation mortality:
United States, 1980–1998. Am J Epidemiol 2002;155:819–826.
3. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the
long-term risks associated with atrial ﬁbrillation: 20-year follow-up of the
Renfrew/Paisley study. Am J Med 2002;113:359–364.
4. Wong CX, Brooks AG, Leong DP, Roberts-Thomson KC, Sanders P. The
increasing burden of atrial ﬁbrillation compared with heart failure and myocardial
infarction: a 15-year study of all hospitalizations in Australia. Arch Intern Med
2012;172:739–741.
5. Botto GL, Padeletti L, Santini M, et al. Presence and duration of atrial ﬁbrillation
detected by continuous monitoring: crucial implications for the risk of throm-
boembolic events. J Cardiovasc Electrophysiol 2009;20:241–248.6. Capucci A, Santini M, Padeletti L, et al. Monitored atrial ﬁbrillation duration
predicts arterial embolic events in patients suffering from bradycardia and atrial
ﬁbrillation implanted with antitachycardia pacemakers. J Am Coll Cardiol
2005;46:1913–1920.
7. Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected
by pacemaker diagnostics predict death and stroke: report of the Atrial
Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation
2003;107:1614–1619.
8. Strickberger SA, Ip J, Saksena S, Curry K, Bahnson TD, Ziegler PD. Relation-
ship between atrial tachyarrhythmias and symptoms. Heart Rhythm 2005;2:
125–131.
9. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, Morillo CA,
Khaykin Y, Birnie D. Discerning the incidence of symptomatic and asympto-
matic episodes of atrial ﬁbrillation before and after catheter ablation
(DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013;173:
149–156.
10. Flaker GC, Belew K, Beckman K, Vidaillet H, Kron J, Safford R, Mickel M,
Barrell P, AFFIRM Investigators. Asymptomatic atrial ﬁbrillation: demo-
graphic features and prognostic information from the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J
2005;149:657–663.
11. Lim HS, Lip GY. Asymptomatic atrial ﬁbrillation on device interrogation.
J Cardiovasc Electrophysiol 2008;19:891–893.
12. Hanke T, Charitos EI, Stierle U, Karluss A, Kraatz E, Graf B, Hagemann A,
Misfeld M, Sievers HH. Twenty-four-hour holter monitor follow-up does not
provide accurate heart rhythm status after surgical atrial ﬁbrillation ablation
therapy: up to 12 months experience with a novel permanently implantable heart
rhythm monitor device. Circulation 2009;120:S177–S184.
13. Kapa S, Epstein AE, Callans DJ, et al. Assessing arrhythmia burden after catheter
ablation of atrial ﬁbrillation using an implantable loop recorder: the ABACUS
study. J Cardiovasc Electrophysiol 2013;24:875–881.
14. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Turov A, Shirokova N,
Karaskov A. Use of an implantable monitor to detect arrhythmia recurrences and
select patients for early repeat catheter ablation for atrial ﬁbrillation: a pilot study.
Circ Arrhythm Electrophysiol 2011;4:823–831.
15. Etgen T, Hochreiter M, Mundel M, Freudenberger T. Insertable cardiac event
recorder in detection of atrial ﬁbrillation after cryptogenic stroke: an audit report.
Stroke 2013;44:2007–2009.
16. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial
ﬁbrillation. N Engl J Med 2014;370:2478–2486.
17. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger
G, Purerfellner H, Investigators XT. Performance of a new leadless implantable
cardiac monitor in detecting and quantifying atrial ﬁbrillation: Results of the
XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141–147.
18. Sarkar S, Ritscher D, Mehra R. A detector for a chronic implantable atrial
tachyarrhythmia monitor. IEEE Trans Biomed Eng 2008;55:1219–1224.
19. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent
monitoring of atrial arrhythmias. Heart Rhythm 2006;3:1445–1452.
20. Purerfellner H, Pokushalov E, Sarkar S, Koehler J, Zhou R, Urban L,
Hindricks G. P-wave evidence as a method for improving algorithm to detect
atrial ﬁbrillation in insertable cardiac monitors. Heart Rhythm 2014;11:
1575–1583.
21. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the
management of patients with atrial ﬁbrillation: a report of the American College
of Cardiology/American Heart Association Task Force on practice guidelines and
the Heart Rhythm Society. Circulation 2014;130:e199–e267.
22. Mittal S, Pokushalov E, Romanov A, Ferrara M, Arshad A, Musat D,
Preminger M, Sichrovsky T, Steinberg JS. Long-term ECG monitoring using
an implantable loop recorder for the detection of atrial ﬁbrillation after
cavotricuspid isthmus ablation in patients with atrial ﬂutter. Heart Rhythm
2013;10:1598–1604.
23. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial ﬁbrillation and the risk
of stroke. N Engl J Med 2012;366:120–129.
